Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Status:
COMPLETED
Trial end date:
2025-06-17
Target enrollment:
Participant gender:
Summary
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity